Obicetrapib is a small molecule commercialized by NewAmsterdam Pharma Company, with a leading Phase III program in Heterozygous familial hypercholesterolemia (heFH). According to Globaldata, it is involved in 22 clinical trials, of which 14 were completed, 3 are ongoing, 4 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Obicetrapib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Obicetrapib is expected to reach an annual total of $453 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Obicetrapib Overview

Obicetrapib (AMG-899, DEZ-001, TA-8995) is under development for Alzheimer’s disease, atherosclerosis, dyslipidemia and heterozygous familial hypercholesterolemia (HeFH) and diabetes. It is administered orally as once daily formulation. The drug candidate acts by targeting cholesteryl ester transfer protein (CETP).

It was under development for was under development for the treatment of mild dyslipidemia by Amgen.

NewAmsterdam Pharma Company Overview

NewAmsterdam Pharma Company (NAP), a clinical stage biotechnology company focused on the research and development of transformative therapies for cardio-renal diseases. The company is headquartered in the Netherlands.

The company reported revenues of (Euro) EUR97.5 million for the fiscal year ended December 2022 (FY2022). The operating loss of the company was EUR67.6 million in FY2022, compared to an operating loss of EUR29.8 million in FY2021. The net loss of the company was EUR78.1 million in FY2022, compared to a net loss of EUR28.6 million in FY2021.

For a complete picture of Obicetrapib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 3 November 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.